Results 211 to 220 of about 16,336,802 (316)

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial

Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Ulus Salih Akarca, Mário Reis Álvares‐da‐Silva, Pietro Andreoné, Marco Arrese, Christophe Corpechot, Hany Elbeshbeshy, Sven Francque, Michael A. Heneghan, Pietro Invernizzi, Ira M. Jacobson, David Jones, Andreas E. Kremer, Frederik C. Kruger, Marcelo Kugelmas, Eric Lawitz, Marlyn J. Mayo, Mitchell L. Shiffman, Mark Sonderup, Mark G. Swain, José Miguel Valera, John M. Vierling, Ares Villagrasa, Alejandra Villamil, Nuno Antunes, Claire Raskino, Marwan Sleiman, Valeria Cranham, Benjamin Miller, Jörn M. Schattenberg   +31 more
openalex   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G. Johnson, Elena Peeva, Michael S. Vincent, Valerie M. Clerin   +11 more
wiley   +1 more source

Conceptual Engineering (CE7): Acknowledging and addressing questions underlying use of Open-Label Placebos

Rahul Arora
openalex   +2 more sources

Combining mindfulness intervention and open-label placebo treatment for chronic pain: a protocol for a feasibility study. [PDF]

Pilot Feasibility Stud
Mun CJ, Contreras E, Xiao Y, Eckert R, Harting A, Damera S, Perez I, Pandey HK, Mardian AS, LoVecchio F, Colloca L, Dunn KE, Todd M, Fillingim RB, Davis MC.   +14 more
europepmc   +1 more source

Lowering salivary pH with sugar‐containing gum augments salivary nitrite production and blood pressure reduction with dietary nitrate (beetroot juice)

British Journal of Clinical Pharmacology, EarlyView.
Acutely lowering salivary pH (with sugar‐containing acidic gum vs. sugar‐free gum) augments salivary nitrate reduction to nitrite, plasma nitrite concentration, and blood pressure lowering with dietary nitrate. Modifying salivary pH reveals a mechanism by which the nitrate‐nitrite‐NO pathway may be upregulated/inhibited, with potential for other ...
Andrew J. Webb, Harriet Clift, Callum Hill, Nur Mousa, Navanithan Arun Jayaraj, Jasmine Quraishi, Charlotte E. Mills, Kevin O'Gallagher   +7 more
wiley   +1 more source

Efficacy of open-label placebos for cardiac anxiety in inpatients with cardiovascular disease: A randomized controlled trial

Sandra Tanzmeister, Laura Harringer, Leon Ludwig Vogel, Anne Schienle   +3 more
openalex   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

P.267 Tibusure: a phase 2, global, randomized, double-blind, placebo-controlled study with open-label extension to evaluate the efficacy, safety, and tolerability of tibulizumab in systemic sclerosis [PDF]

Christopher P Denton, Brandon Walsh, Vaishali Moulton, Shelly Shirkey, Kate Lindsell, Marjan Sepassi, Kiran Nistala, D Khanna   +7 more
openalex   +1 more source

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, Juan José Perez Ruixo, Saberi Rana Ali, Iolanda Cirillo, Oliver Ackaert   +6 more
wiley   +1 more source

A systematic review and meta analysis of open label placebo effects in chronic musculoskeletal pain. [PDF]

Sci Rep
Borg F, Gedin F, Franzén E, Grooten WJA.   +3 more
europepmc   +1 more source